Cancer has been the most common cause of death in Korea since 1983 and is a major public health concern. This paper overviews the nationwide cancer statistics, including incidence, mortality, and survival rates, and their trends in Korea. In 2005, 142,610 new cancer cases and 65,117 cancer deaths occurred in Korea. The incidence rate for all cancer combined increased by 2.6% annually from 1999 to 2005. Significant increases have occurred in the incidence of colorectal, thyroid, female breast, and prostate cancers. The number of cancer deaths has increased over the past two decades, due mostly to population aging, while the age-standardized mortality rates have decreased in both men and women since 2002. Notable improvement has been observed in the 5-yr relative survival rates for most major cancers and for all cancer combined, with the exception of pancreatic cancer. The nationwide cancer statistics in this paper will provide essential data for evidence-based decisions in the national cancer control program in Korea.

Key Words : Incidence; Mortality; Survival; Neoplasms; Korea

INTRODUCTION

Cancer has been the most common cause of death in Korea since 1983 (1) and poses a major public health concern. Over 140,000 new cancer cases are diagnosed annually in Korea and one out of four deaths results from cancer (2, 3). This paper gives an overview of the nationwide cancer statistics, including the incidence, mortality, and survival rates, and their trends in Korea. This report is a part of Special Article series that presents the annually updated nationwide cancer statistics in Korea.

MATERIALS AND METHODS

Data sources

The Korea Ministry of Health and Welfare started a nationwide, hospital-based cancer registry called the Korea Central Cancer Registry (KCCR) in 1980. Details of the history, objectives, and activities of the KCCR have been documented (4). Incidence data from 1999 to 2005 were obtained from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology 3rd edition (5) and converted according to the International Classification of Diseases 10th edi-
tion (ICD-10) (6). The survival analysis used 1,151,789 cancer cases first diagnosed during 1993-2005 from the KNCI DB, and followed vital status through 31 December 2006.

Mortality data from 1983 to 2005 were obtained from the Korea National Statistics Office (KNSO) (1). Cause of death was coded and classified according to the ICD-10. The population data were also obtained from KNSO using the resident registration population on 1 July.

Analysis

Crude rates (CRs) and age-specific rates of cancer incidence and mortality were calculated. Age-standardized rates (ASRs) were determined using the World Health Organization (WHO) world standard population (7). The cumulative risks of cancer incidence, which are the probability of developing cancer to the life expectancy, were also calculated. Changes in the annual age-standardized cancer incidence rates were examined by calculating the annual percentage change (APC) over a time period as 100(e^-1), where e is the slope of the regression of log age-standardized rates on a calendar year (8).

The survival duration of each case was determined as the time difference between the date of initial diagnosis and the date of death, date of loss to follow-up, or closing date for follow-up. Observed survival rates were calculated using a life table method and relative survival rates were examined with the Ederer II method (9) using an algorithm written in SAS by Paul Dickman (10), with some minor adaptations.

SELECTED FINDINGS

Incidence

Table 1 presents the number of new cancer cases during 2005 in Korea by sex and cancer site. In 2005, 142,610 cancer incident cases were observed. The CRs of all sites combined were 317.8 and 268.0 per 100,000 in men and women, respectively, and the ASRs of all sites combined were 303.5 and 201.4 per 100,000 (Table 2). The cumulative risks for developing a cancer to the life expectancy were 32.3% for men and 26.5% for women.

Table 1. Number of cancer cases and deaths by sex during 2005 in Korea

| Sites                      | New cases |   | Deaths |   |
|----------------------------|-----------|---|--------|---|
|                            | Both sexes| Males| Females| Males| Females|
| All sites                  | 142,610   | 77,566| 65,044 | 65,117| 41,131| 23,986 |
| Lip, oral cavity & pharynx | 2,151     | 1,558| 593    | 844  | 650   | 194   |
| Esophagus                  | 2,019     | 1,864| 155    | 1,422| 1,309 | 113   |
| Stomach                    | 25,809    | 17,024| 8,785 | 10,935| 7,146 | 3,789 |
| Colon & rectum             | 17,625    | 10,253| 7,372 | 5,997| 3,259 | 2,738 |
| Liver                      | 14,907    | 11,264| 3,643 | 10,877| 8,188 | 2,689 |
| Gallbladder*               | 4,166     | 2,094| 2,072 | 3,328| 1,694 | 1,634 |
| Pancreas                   | 3,703     | 2,050| 1,653 | 3,373| 1,862 | 1,511 |
| Larynx                     | 1,132     | 1,047| 85    | 629  | 567   | 62    |
| Lung                       | 16,949    | 12,339| 4,610 | 13,733| 10,098| 3,635 |
| Breast                     | 9,898     | 56   | 9,842 | 1,589| 16    | 1,573 |
| Cervix uteri               | 3,737     | 3,737| -     | 1,066| -     | -     |
| Corpus uteri               | 1,146     | 1,146| -     | 151  | -     | 151   |
| Ovary                      | 1,544     | 1,544| -     | 751  | -     | 751   |
| Prostate                   | 3,487     | 3,487| -     | 900  | 900   | -     |
| Testis                     | 148       | 148  | -     | 11   | 11    | -     |
| Kidney                     | 2,299     | 1,569| 730   | 658  | 449   | 209   |
| Bladder                    | 2,905     | 2,331| 574   | 905  | 674   | 231   |
| Brain & CNS                | 1,552     | 810  | 742   | 1,163| 622   | 541   |
| Thyroid                    | 12,649    | 1,765| 10,884| 327  | 83    | 244   |
| Hodgkin's disease          | 154       | 154  | 50    | 35   | 25    | 10    |
| Non-Hodgkin's lymphoma     | 2,937     | 1,640| 1,297 | 1,253| 760   | 493   |
| Multiple myeloma           | 772       | 400  | 372   | 521  | 270   | 251   |
| Leukemia                   | 2,289     | 1,232| 997   | 1,438| 794   | 644   |
| Other & ill-defined        | 8,632     | 4,471| 4,161 | 3,211| 1,754 | 1,457 |

*Includes gallbladder and other/unspecified parts of biliary tract.
CNS, central nervous system.
Common cancer sites were the thyroid (CR 44.8, ASR 35.0), breast (CR 40.5, ASR 31.0), stomach (CR 36.2, ASR 26.3), colon & rectum (CR 30.4, ASR 22.2), lung (CR 19.0, ASR 13.2), and cervix uteri (CR 15.4, ASR 11.5), accounting for about 69% of all newly diagnosed cancers.

From the construction of a KNCI DB for 1999 onward to 2005, the completeness of the Korea cancer registry data has improved gradually. This might have contributed in part to the gradual overall increases in cancer incidence, especially among the elderly. Nonetheless, the increases in thyroid, colorectal and breast cancers in women and prostate cancer in men are notable.

**Mortality**

In 2005, 65,117 cancer deaths were reported in Korea, accounting for about 26.7% of all deaths (Table 3). The CRs of all sites combined were 168.5 and 98.8 per 100,000 for men and women, respectively, and the ASRs of all sites combined were 166.6 and 68.8 per 100,000 (Table 4). Cancers of the lung, stomach, liver and colon & rectum were the most common fatal cancers, which accounted for 64% of all cancer deaths.

In men, the five leading primary cancer sites for mortality were the lung (CR 41.4, ASR 41.7), liver (CR 33.5, ASR 31.1), stomach (CR 29.3, ASR 28.9), colon & rectum (CR 13.4, ASR 13.5), and pancreas (CR 7.6, ASR 7.6). In women, the most common cancer sites for mortality were the stomach (CR 15.6, ASR 10.5), lung (CR 15.0, ASR 10.0), colon

| Sites                      | Both sexes | Males | Females |
|----------------------------|------------|-------|---------|
| All sites                  | 292.9      | 317.8 | 268.0   |
| Lip, oral cavity & pharynx | 4.4        | 6.4   | 2.4     |
| Esophagus                  | 4.7        | 7.6   | 0.6     |
| Stomach                    | 53.0       | 69.7  | 36.2    |
| Colon & rectum             | 36.2       | 42.0  | 30.4    |
| Liver                      | 30.6       | 46.1  | 15.0    |
| Gallbladder                | 8.6        | 8.6   | 8.5     |
| Pancreas                   | 7.6        | 8.4   | 6.8     |
| Larynx                     | 2.3        | 4.3   | 0.4     |
| Lung                       | 34.8       | 50.5  | 19.0    |
| Breast                     | 20.3       | 0.2   | 40.5    |
| Cervix uteri               | -          | -     | 15.4    |
| Corpus uteri               | -          | -     | 4.7     |
| Ovary                      | -          | -     | 6.4     |
| Prostate                   | -          | 14.3  | -       |
| Testis                     | -          | 0.6   | -       |
| Kidney                     | 4.7        | 6.4   | 3.0     |
| Bladder                    | 6.0        | 9.5   | 2.4     |
| Brain & CNS                | 3.2        | 3.3   | 3.1     |
| Thyroid                    | 26.0       | 7.2   | 44.8    |
| Hodgkin’s disease          | 0.3        | 0.4   | 0.2     |
| Non-Hodgkin’s lymphoma     | 6.0        | 6.7   | 5.3     |
| Multiple myeloma           | 1.6        | 1.6   | 1.5     |
| Leukemia                   | 4.7        | 5.3   | 4.1     |
| Other & ill-defined        | 17.7       | 18.3  | 17.1    |

*Age-standardized to the WHO world standard population; †Includes gallbladder and other/unspecified parts of biliary tract. CNS, central nervous system.
& rectum (CR 11.3, ASR 7.5), liver (CR 11.1, ASR 7.9), and gallbladder (CR 6.7, ASR 4.5).

**Trends in cancer incidence**

Tables 5.1-5.3 show the trends in cancer incidence for all sites combined and for selected cancer sites. The incidence rate for all sites combined increased by 2.5% annually from 1999 to 2005. The incidence rate for all sites combined increased by 1.2% annually in men and by 4.1% in women from 1999 to 2005.

The incidence rates have continued to increase for colorectal and thyroid cancer in both sexes, along with breast cancer in females and prostate cancer in males. Stomach and lung cancer incidence rates plateaued in men and women, while the incidences of liver cancer in both sexes and the cervix in women have decreased.

One notable aspect is the sharp increase (25.1% annually) in the incidence of female thyroid cancer. As diagnostic techniques for thyroid cancer have become more sensitive, such as with the advent of ultrasound and fine-needle aspiration, the detection of subclinical disease has become possible. Therefore, the increased incidence of thyroid cancer might reflect improved diagnostic techniques for previously undetected disease, rather than a true increase in the occurrence of thyroid cancer (11, 12).

---

**Table 4. Crude and age-standardized cancer mortality rates by sex during 2005 in Korea**

| Sites                        | Crude mortality rates per 100,000 | Age-standardized mortality rates per 100,000* |
|------------------------------|----------------------------------|---------------------------------------------|
|                              | Both sexes | Males | Females | Both sexes | Males | Females |
| All sites                    | 133.8      | 168.5 | 98.8     | 109.1      | 166.6 | 68.8     |
| Lip, oral cavity & pharynx   | 1.7        | 2.7   | 0.8      | 1.4        | 2.5   | 0.6      |
| Esophagus                    | 2.9        | 5.4   | 0.5      | 2.4        | 5.3   | 0.3      |
| Stomach                      | 22.5       | 29.3  | 15.6     | 18.0       | 28.9  | 10.5     |
| Colon & rectum               | 12.3       | 13.4  | 11.3     | 9.9        | 13.5  | 7.5      |
| Liver                        | 22.3       | 32.5  | 11.1     | 18.5       | 31.1  | 7.5      |
| Gallbladder & other/unspecified parts of biliary tract | 6.8 | 6.9 | 6.7 | 5.5 | 7.0 | 4.5 |  
| Pancreas                     | 6.9        | 7.6   | 6.2      | 5.7        | 7.6   | 4.2      |
| Larynx                       | 1.3        | 2.3   | 0.3      | 1.0        | 2.4   | 0.2      |
| Lung                         | 28.2       | 41.4  | 15.0     | 22.9       | 41.7  | 10.0     |
| Breast                       | 3.3        | 0.1   | 6.5      | 2.6        | 0.1   | 4.9      |
| Cervix uteri                 | -          | -     | 4.4      | -          | -     | 3.1      |
| Corpus uteri                 | -          | -     | 0.6      | -          | -     | 0.5      |
| Ovary                        | -          | -     | 3.1      | -          | -     | 2.3      |
| Prostate                     | -          | 3.7   | -        | -          | 4.3   | -        |
| Testis                       | -          | 0.0   | -        | -          | 0.0   | -        |
| Kidney                       | 1.4        | 1.8   | 0.9      | 1.1        | 1.8   | 0.6      |
| Bladder                      | 1.9        | 2.8   | 1.0      | 1.5        | 3.0   | 0.6      |
| Brain & CNS                  | 2.4        | 2.5   | 2.2      | 2.1        | 2.4   | 1.8      |
| Thyroid                      | 0.7        | 0.3   | 1.0      | 0.5        | 0.3   | 0.7      |
| Hodgkin’s disease            | 0.1        | 0.1   | 0.0      | 0.1        | 0.1   | 0.0      |
| Non-Hodgkin’s lymphoma       | 2.6        | 3.1   | 2.0      | 2.1        | 3.0   | 1.5      |
| Multiple myeloma             | 1.1        | 1.1   | 1.0      | 0.9        | 1.1   | 0.7      |
| Leukemia                     | 3.0        | 3.3   | 2.7      | 2.7        | 3.3   | 2.2      |
| Other & ill-defined          | 6.6        | 7.2   | 6.0      | 5.5        | 7.3   | 4.3      |

*Age-standardized to the WHO world standard population; † includes gallbladder and other/unspecified parts of biliary tract.

CNS, central nervous system.

**Fig. 1. Annual age-standardized cancer incidence and death rates for all sites by sex during 1983-2005 in Korea.**
Table 5-1. Trends in cancer incidence rates in both sexes during 1999-2005 in Korea

| Sites                          | 1999  | 2000  | 2001  | 2002  | 2003  | 2004  | 2005  | APC* |
|-------------------------------|-------|-------|-------|-------|-------|-------|-------|------|
| All sites                     | 210.5 | 205.1 | 216.7 | 220.1 | 225.2 | 230.8 | 240.8 | 2.5  |
| Lip, oral cavity & pharynx    | 3.6   | 4.4   | 3.6   | 3.7   | 3.7   | 3.7   | 3.7   | -0.9 |
| Esophagus                     | 4.1   | 3.7   | 3.9   | 3.8   | 3.6   | 3.5   | 3.5   | -2.1 |
| Stomach                       | 43.6  | 42.3  | 44.0  | 43.6  | 43.1  | 40.5  | 43.4  | -0.4 |
| Colon & rectum                | 20.4  | 21.0  | 22.9  | 24.7  | 26.4  | 27.9  | 29.8  | 6.8  |
| Liver                         | 27.9  | 26.7  | 27.3  | 26.5  | 25.7  | 25.4  | 25.4  | -1.6 |
| Gallbladder                   | 6.5   | 6.4   | 6.7   | 6.7   | 6.6   | 6.9   | 7.0   | 1.3  |
| Pancreas                      | 5.6   | 5.5   | 5.5   | 5.8   | 5.8   | 6.0   | 6.2   | 1.9  |
| Larynx                        | 2.3   | 2.2   | 2.4   | 2.2   | 2.1   | 1.9   | 2.0   | -3.3 |
| Lung                          | 28.5  | 27.7  | 28.3  | 28.5  | 27.8  | 28.6  | 28.5  | 0.2  |
| Breast                        | 10.7  | 10.8  | 12.7  | 13.9  | 14.0  | 14.5  | 15.8  | 6.5  |
| Kidney                        | 3.0   | 2.9   | 3.3   | 3.4   | 3.5   | 3.7   | 4.0   | 5.1  |
| Bladder                       | 4.6   | 4.6   | 4.9   | 4.7   | 5.0   | 5.0   | 4.9   | 1.3  |
| Brain & CNS                   | 2.9   | 2.8   | 2.8   | 2.6   | 2.9   | 2.9   | 3.0   | 0.8  |
| Thyroid                       | 6.3   | 6.1   | 7.9   | 9.5   | 12.5  | 17.2  | 20.5  | 24.2 |
| Hodgkin’s disease             | 0.2   | 0.3   | 0.3   | 0.3   | 0.3   | 0.4   | 0.3   | 4.4  |
| Non-Hodgkin’s lymphoma        | 4.5   | 4.2   | 4.5   | 4.6   | 4.9   | 5.1   | 5.1   | 3.2  |
| Multiple myeloma              | 1.0   | 1.0   | 1.1   | 1.1   | 1.1   | 1.2   | 1.3   | 4.2  |
| Leukemia                      | 4.7   | 4.3   | 4.7   | 4.8   | 4.7   | 4.7   | 4.6   | 0.7  |
| Other & ill-defined           | 14.3  | 13.5  | 13.9  | 13.5  | 14.6  | 14.5  | 15.2  | 1.4  |

Table 5-2. Trends in cancer incidence rates in males during 1999-2005 in Korea

| Sites                          | 1999  | 2000  | 2001  | 2002  | 2003  | 2004  | 2005  | APC* |
|-------------------------------|-------|-------|-------|-------|-------|-------|-------|------|
| All sites                     | 285.0 | 276.7 | 288.3 | 290.0 | 292.3 | 294.8 | 303.5 | 1.2  |
| Lip, oral cavity & pharynx    | 6.1   | 7.1   | 6.0   | 6.2   | 6.4   | 6.0   | 5.9   | -1.3 |
| Esophagus                     | 8.8   | 8.0   | 8.3   | 8.2   | 7.7   | 7.6   | 7.5   | -2.2 |
| Stomach                       | 66.2  | 65.0  | 67.2  | 66.6  | 65.7  | 61.5  | 65.5  | -0.6 |
| Colon & rectum                | 26.2  | 27.2  | 29.6  | 32.9  | 34.7  | 36.9  | 39.6  | 7.5  |
| Liver                         | 46.8  | 44.7  | 45.1  | 43.9  | 42.3  | 42.0  | 42.0  | -1.8 |
| Gallbladder                   | 8.1   | 7.8   | 8.2   | 8.1   | 7.8   | 8.4   | 8.6   | 1.0  |
| Pancreas                      | 7.8   | 7.6   | 7.6   | 7.9   | 7.7   | 8.0   | 8.2   | 0.9  |
| Larynx                        | 4.9   | 4.5   | 5.1   | 4.7   | 4.4   | 4.0   | 4.2   | -3.0 |
| Lung                          | 51.4  | 49.8  | 51.1  | 51.0  | 49.9  | 50.6  | 50.2  | -0.2 |
| Breast                        | 0.2   | 0.3   | 0.2   | 0.3   | 0.2   | 0.2   | 0.2   | -0.7 |
| Prostate                      | 8.4   | 7.2   | 9.5   | 10.1  | 12.0  | 14.4  | 14.7  | 12.6 |
| Testis                        | 0.6   | 0.5   | 0.6   | 0.6   | 0.6   | 0.5   | 0.5   | 1.1  |
| Kidney                        | 4.5   | 4.4   | 4.9   | 5.0   | 5.1   | 5.5   | 5.9   | 4.6  |
| Bladder                       | 9.0   | 9.0   | 9.4   | 9.0   | 9.6   | 9.5   | 9.4   | 1.0  |
| Brain & CNS                   | 3.2   | 3.1   | 3.1   | 2.9   | 3.3   | 3.3   | 3.3   | 0.8  |
| Thyroid                       | 2.1   | 1.9   | 2.4   | 2.7   | 3.6   | 4.8   | 5.8   | 20.7 |
| Hodgkin’s disease             | 0.4   | 0.4   | 0.4   | 0.3   | 0.4   | 0.5   | 0.4   | 3.4  |
| Non-Hodgkin’s lymphoma        | 5.8   | 5.5   | 5.8   | 5.8   | 6.1   | 6.5   | 6.3   | 2.2  |
| Multiple myeloma              | 1.2   | 1.3   | 1.4   | 1.4   | 1.4   | 1.6   | 1.6   | 3.8  |
| Leukemia                      | 5.5   | 5.0   | 5.4   | 5.8   | 5.4   | 5.6   | 5.4   | 0.7  |
| Other & ill-defined           | 17.9  | 16.5  | 16.8  | 16.5  | 17.9  | 17.4  | 18.1  | 0.8  |

*a annual percent change using age-standardized incidence based on the WHO world standard population; °Includes gallbladder and other/unspecified parts of biliary tract; †The APC is significantly different from zero (P<0.05). CNS, central nervous system.
Trends in cancer mortality

Figs. 1 & 2 show the trends in cancer deaths for all sites combined and for selected cancer sites. Age-standardized mortality rates have decreased for all sites combined in both sexes since 2002.

For lung cancer, the leading site for cancer deaths since 1999, mortality has decreased slightly for men since 2001, but increased significantly in women. The age-standardized mortality rates of stomach and cervix uteri cancer have decreased continuously. Along with the significant increases in colorectal, prostate and female breast cancer incidence, the mortality rates of these cancers have also continued to increase.
Table 6. Five major sites of cancer incidence by age group and sex during 2005 in Korea

| Rank | Age-specific incidence rate per 100,000 |
|------|--------------------------------------|
|      | 0-14 yr  | 15-34 yr | 35-64 yr | 65 yr and over |
| Males |          |          |          |                |
| 1     | Leukemia | Stomach  | Stomach  | Lung           |
|       | (4.1)    | (3.9)    | (92.3)   | (478.6)        |
| 2     | Brain & CNS | Thyroid | Liver    | Stomach        |
|       | (2.1)    | (3.5)    | (74.8)   | (454.5)        |
| 3     | Non-Hodgkin’s lymphoma | Leukemia | Colon & rectum | Colon & rectum |
|       | (1.4)    | (3.1)    | (55.5)   | (274.5)        |
| 4     | Liver    | Non-Hodgkin’s lymphoma | Lung | Liver |
|       | (0.5)    | (2.3)    | (43.8)   | (220.0)        |
| 5     | Kidney   | Colon & rectum | Thyroid | Prostate |
|       | (0.4)    | (2.3)    | (12.8)   | (157.0)        |

| Rank | Age-specific incidence rate per 100,000 |
|------|--------------------------------------|
|      | 0-14 yr  | 15-34 yr | 35-64 yr | 65 yr and over |
| Females |          |          |          |                |
| 1     | Leukemia | Thyroid  | Breast   | Stomach        |
|       | (3.6)    | (23.9)   | (82.1)   | (165.8)        |
| 2     | Brain & CNS | Breast | Thyroid | Colon & rectum |
|       | (1.8)    | (9.6)    | (81.6)   | (150.3)        |
| 3     | Non-Hodgkin’s lymphoma | Stomach | Stomach | Lung |
|       | (0.8)    | (4.8)    | (42.3)   | (116.3)        |
| 4     | Ovary    | Cervix uteri | Colon & rectum | Liver |
|       | (0.6)    | (4.1)    | (34.3)   | (74.2)         |
| 5     | Kidney   | Ovary    | Cervix uteri | Gallbladder* |
|       | (0.4)    | (2.8)    | (25.7)   | (54.6)         |

*Includes gallbladder and other/unspecified parts of biliary tract.
CNS, central nervous system.

Fig. 3. Age-specific incidence rates of major cancers during 2005 in Korea.

Age-specific incidence rates for selected cancer sites

Table 6 presents the most common cancer sites by sex and age group. For ages 0-14 yr, leukemia was the most common form in both sexes. For males, stomach cancer was the most common in 15-64-yr-olds, while lung cancer was more frequent for those 65 and over. For females, the most common sites of cancer were the thyroid, breast and stomach for the 15-34-yr-old, 35-64-yr-old, and the 65 and over age groups, respectively. Fig. 3 shows the age-specific incidence rates of the selected cancers for men and women. The data show that the incidence of stomach, lung, liver and colorectal cancers increased gradually with age. In women, the age-specific incidence rates of breast and thyroid cancer has increased with age until the forties and decreased thereafter.

Survival rates

Table 7 shows the 5-yr relative survivals for three periods: 1993-1995, 1996-2000, and 2001-2005. Notable improvement has been made in the 5-yr relative survival rates for all sites combined. The survival of females appears to have a better prognosis than that of males. This is partly explained by the high frequency of female cancers (e.g., thyroid, breast and uterine cervix) known to have relatively good prognoses.

The 5-yr relative survival rates appeared to be higher for most major cancer sites in patients diagnosed during 2001-2005 compared to 1993-1995, except for cancers of the pancreas, brain and central nervous system. The greatest improvements were seen in leukemia, non-Hodgkin’s lymphoma,
and prostate, stomach, colorectal and breast cancers.

The improving survival rates could be attributable to early detection, as well as to improved treatments (13, 14), but this needs to be evaluated further. Lack of progress in early detection and treatment could explain the observed absence of improvement in the survival rate of pancreatic cancer (15).

### Table 7. Trends in the 5-yr relative survival rates (%) by year of diagnosis during 1993-2005 in Korea

| Sites                          | Males | 1993-1995 | 1996-2000 | 2001-2005 | Change* | Females | 1993-1995 | 1996-2000 | 2001-2005 | Change* |
|-------------------------------|-------|-----------|-----------|-----------|---------|---------|-----------|-----------|-----------|---------|
| All sites                     | 31.7  | 35.3      | 43.7      | 12.0      |         | 53.4    | 55.3      | 62.4      | 9.0       |
| Lip, oral cavity & pharynx    | 35.8  | 41.1      | 46.9      | 11.1      |         | 56.1    | 63.8      | 65.4      | 7.3       |
| Esophagus                     | 11.6  | 14.3      | 19.5      | 7.7       |         | 23.7    | 24.2      | 27.1      | 3.4       |
| Stomach                      | 43.0  | 46.9      | 57.0      | 14.0      |         | 42.6    | 46.0      | 55.1      | 12.5      |
| Colon & rectum                | 55.3  | 59.0      | 66.7      | 11.4      |         | 54.2    | 56.8      | 62.4      | 8.2       |
| Liver                        | 9.9   | 12.9      | 18.8      | 8.9       |         | 13.6    | 14.2      | 19.0      | 5.4       |
| Gallbladder*                  | 16.6  | 20.3      | 23.0      | 6.4       |         | 18.0    | 19.1      | 21.7      | 3.7       |
| Pancreas                      | 8.8   | 7.3       | 8.0       | -0.8      |         | 10.1    | 7.3       | 7.6       | -2.5      |
| Larynx                       | 60.2  | 62.8      | 65.8      | 5.6       |         | 55.4    | 57.8      | 58.3      | 2.9       |
| Lung                         | 10.4  | 11.6      | 14.1      | 3.7       |         | 14.2    | 16.2      | 19.4      | 5.2       |
| Breast                       | 75.1  | 85.6      | 87.1      | 12.0      |         | 78.0    | 83.2      | 87.3      | 9.3       |
| Cervix uteri                 | -     | -         | -         | -         |         | 77.5    | 80.0      | 81.1      | 3.6       |
| Corpus uteri                 | -     | -         | -         | -         |         | 81.5    | 81.8      | 84.5      | 3.0       |
| Ovary                        | -     | -         | -         | -         |         | 58.7    | 58.9      | 62.1      | 3.4       |
| Prostate                     | 55.9  | 67.2      | 76.9      | 21.0      |         | -       | -         | -         | -         |
| Testis                       | 85.4  | 90.4      | 90.0      | 4.6       |         | -       | -         | -         | -         |
| Kidney                       | 60.8  | 64.4      | 71.3      | 10.5      |         | 64.5    | 69.7      | 74.4      | 9.9       |
| Bladder                      | 70.0  | 74.8      | 78.8      | 8.8       |         | 65.5    | 66.3      | 68.3      | 2.8       |
| Brain & CNS                  | 37.2  | 37.5      | 38.0      | 0.8       |         | 40.2    | 40.7      | 39.9      | -0.3      |
| Thyroid                      | 87.2  | 89.5      | 95.7      | 8.5       |         | 95.4    | 95.9      | 98.5      | 3.1       |
| Hodgkin’s disease            | 67.6  | 68.1      | 73.3      | 5.7       |         | 68.6    | 77.4      | 76.2      | 7.6       |
| Non-Hodgkin’s lymphoma       | 45.3  | 48.9      | 56.0      | 10.7      |         | 48.7    | 53.5      | 60.8      | 12.1      |
| Multiple myeloma             | 21.1  | 17.8      | 30.2      | 9.1       |         | 23.3    | 22.1      | 27.6      | 4.3       |
| Leukemia                     | 26.2  | 32.3      | 39.4      | 13.2      |         | 26.8    | 34.6      | 40.9      | 14.1      |
| Other & ill-defined          | 37.4  | 42.4      | 51.1      | 13.7      |         | 47.4    | 50.0      | 57.7      | 10.3      |

*Change in the 5-yr relative survival between 1993-1995 and 2001-2005 as a percentage; †Includes gallbladder and other/unspecified parts of biliary tract. CNS, central nervous system.

### References

1. National Statistical Office. 2008. Available at http://kosis.nso.go.kr [Accessed 14 April 2009].
2. Ministry for Health, Welfare and Family Affairs. Annual report of cancer incidence (2005) and survival (1993-2005) in Korea; 2008.
3. Won YJ, Sung J, Jung KW, Hong JH, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DK, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong JS, Lee DH, Lee JS. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009; 41: 122-31.
4. Shin HR, Won YJ, Jung KW, Hong JH, Yim SH, Lee JK, Noh HJ, Lee JK, Pisani P, Park JG, Ahn YO, Lee SY, Lee CW, Woo ZH, Lee TY, Choi JS, Yoo CI, Bae JM. Nationwide cancer incidence in Korea, 1999-2001; first result using the National Cancer Incidence Database. Cancer Res Treat 2005; 37: 325-31.
5. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S, eds. International classification of diseases for oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
6. Manual of the international statistical classification of diseases, injuries, and causes of death, 10th revision. Geneva, Switzerland: World Health Organization; 1992.
7. Segi M. Cancer Mortality for selected sites in 24 countries (1950-1957). Sendai, Japan: Tohoku University School of Medicine; 1960.
8. Ries L, Harkins D, Krapcho M, Mariotto A, Miller B, Feuer E, Clegg L, Eisner M, Horner N, Hayat M, Hankey B, Edwars BE. SEER cancer statistics review, 1973-2003. Available at http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER Web site, 2006, Bethesda, MD: National Cancer Institute. [Accessed 12 September 2006].
9. Ederer F, Heise H. Instructions to IBM programmers in processing survival computations. Methodological note No. 10, Bethesda, MD: National Cancer Institute; 1959.
10. Dickman P. Available at http://www.paulldickman.com [Accessed 14 April 2009].
11. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-7.
12. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS. Rising thyroid cancer incidence in the United States by
demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009; 18: 784-91.
13. Jung KW, Yim SH, Kong HJ, Hwang SY, Won YJ, Lee JK, Shin HR. Cancer survival in Korea 1993-2002: a population-based study. J Korean Med Sci 2007; 22 (Suppl): S5-10.
14. Gondos A, Bray F, Hakulinen T, Brenner H; EUNICE Survival Working Group. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 2009; 20: 564-73.
15. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med 2006; 260: 103-17.